Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.47 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.47 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.47 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | IDH1 | O75874 | 6/20 | 0.41 |
| ▸ | IDH2 | P48735 | 1/20 | 0.41 |
| ▸ | PGK1 | P00558 | 1/20 | 0.38 |
| ▸ | PGK2 | P07205 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.38 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 2/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CCR6 | P51684 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NT5E | P21589 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL955898 | 0.86 | PGK1 (0.38) | GABRA1GABRG2GABRB3GABRA3P2RX7 | |
| SCHEMBL1275087 | 0.82 | SYK (0.46) | GABRA1GABRG2GABRB3GABRA3IDH1 | |
| SCHEMBL30041313 | 0.82 | GABRA1 (0.36) | GABRA1GABRG2GABRB3GABRA3P2RX7 | |
| SCHEMBL29272376 | 0.82 | GABRA1 (0.36) | GABRA1GABRG2GABRB3GABRA3P2RX7 | |
| SCHEMBL906764 | 0.82 | GABRA1 (0.36) | GABRA1GABRG2GABRB3GABRA3P2RX7 | |
| SCHEMBL5646151 | 0.82 | GABRA1 (0.36) | GABRA1GABRG2GABRB3GABRA3P2RX7 | |
| SCHEMBL31078226 | 0.82 | IDH1 (0.37) | GABRA1GABRG2GABRB3GABRA3P2RX7 | |
| SCHEMBL1437359 | 0.82 | IDH1 (0.37) | GABRA1GABRG2GABRB3GABRA3P2RX7 | |
| SCHEMBL3295150 | 0.82 | P2RX7 (0.50) | GABRA1GABRG2GABRB3GABRA3P2RX7 | |
| SCHEMBL10056575 | 0.80 | CYP3A4 (0.34) | GABRA1GABRG2GABRB3GABRA3PGK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 812 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111662271-B | Compound with IDH mutant inhibitory activity and preparation method and application thereof | 中国药科大学 | 2023-11-14 | — | — | CN | claimed |
| WO-2022130403-A1 | NEW QUATERNARY AMMONIUM SALTS FOR TRIFLUOROMETHYLATION AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2022-06-23 | — | — | WO | claimed |
| CN-111662271-A | Compound with IDH mutant inhibitory activity and preparation method and application thereof | 中国药科大学 | 2020-09-15 | — | — | CN | claimed |
| CN-104447519-B | A method of preparing the bromo- 6- trifluoromethyl pyridine of 3- substitution -2- | 成都安斯利生物医药有限公司 | 2019-01-22 | — | — | CN | claimed |
| US-20260083851-A1 | POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2026-03-26 | — | — | US | disclosed |
| US-20260078091-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC (US) | 2026-03-19 | — | — | US | disclosed |
| EP-3704094-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4688738-A1 | HETEROCYCLOALKYL BETA-HYDROXY ALKYL AMINES FOR USE IN THE TREATMENT OF HYPERGLYCAEMIA AND DISORDERS CHARACTERISED BY HYPERGLYCAEMIA | Atrogi AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| US-12509470-B2 | Antiviral heterocyclic compounds | ENANTA PHARMACEUTICALS, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250333405-A1 | ANTAGONISTS OF GPR39 PROTEIN | VASOCARDEA INC (US) | 2025-10-30 | — | — | US | disclosed |
| EP-4612140-A1 | NEK7 DEGRADERS AND METHODS OF USE THEREOF | Captor Therapeutics S.A. (PL) | 2025-09-10 | — | — | EP | disclosed |
| US-20250270202-A1 | SUBSTITUTED 4-AMINOISOINDOLINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2025-08-28 | — | — | US | disclosed |
| US-20040014634-A1 | Thieno[2,3-d]pyrimidinediones and their use as pharmaceuticals | ASTRAZENECA AB (SE) | 2004-01-22 | — | — | US | disclosed |
| EP-1107973-B1 | NOVEL THIENO[2,3-d]PYRIMIDINEDIONES, PROCESS FOR THEIR PREPARATION AND USE THEREOF IN THERAPY | ASTRAZENECA AB (SE) | 2003-11-05 | — | — | EP | disclosed |
| EP-1280806-A1 | THIENO 2,3-d]PYRIMIDINEDIONES AND THEIR USE AS PHARMACEUTICALS | AstraZeneca AB (SE) | 2003-02-05 | — | — | EP | disclosed |
| WO-2001083489-A1 | THIENO[2,3-d]PYRIMIDINEDIONES AND THEIR USE AS PHARMACEUTICALS | ASTRAZENECA AB (SE) | 2001-11-08 | — | — | WO | disclosed |
| US-6300334-B1 | DRUGS FOR TREATMENT OF RESPIRATORY SYSTEM DISORDERS | ASTRAZENECA AB (SE) | 2001-10-09 | — | — | US | disclosed |
| EP-1107973-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2001-06-20 | — | — | EP | disclosed |
| WO-2000012514-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2000-03-09 | — | — | WO | disclosed |
| WO-1997012883-A1 | INTERMEDIATES AND PROCESS FOR THE PREPARATION OF SUBSTITUTED SALICYLIC ACID DERIVATIVES AS PLANT PROTECTIVE AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 1997-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078091-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | TP53, HIF1AN, MDM2 | GABRA1 4459/4885GABRG2 4714/4885GABRB3 4614/4885 |
| US-12509470-B2 | Antiviral heterocyclic compounds | NR3C1, ZC3HAV1, HAVCR2 | GABRA1 1242/4885GABRG2 1783/4885GABRB3 1200/4885 |
| US-20260083851-A1 | POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | ASGR1, FCGR2A, FCGR3B | GABRA1 223/4885GABRG2 190/4885GABRB3 282/4885 |
| US-20040014634-A1 | Thieno[2,3-d]pyrimidinediones and their use as pharmaceuticals | DPYD, TYMP, TYMS | GABRA1 2618/4885GABRG2 2971/4885GABRB3 2994/4885 |
| US-20250270202-A1 | SUBSTITUTED 4-AMINOISOINDOLINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | CUL4B, CUL3, CUL4A | GABRA1 596/4885GABRG2 1065/4885GABRB3 281/4885 |
| US-20250333405-A1 | ANTAGONISTS OF GPR39 PROTEIN | GPR39, GPR139, GPR119 | GABRA1 336/4885GABRG2 374/4885GABRB3 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.